CERS News and Press, Cerus Corporation From 12/15/20

Cerus Corporation (Nasdaq: CERS) today announced that its distribution partner, Companhia Energética Integrada (CEI), was awarded a three-year contract with the HemoMinas Foundation (“HemoMinas”) of Brazil for the INTERCEPT Blood System for platelets. HemoMinas provid...

Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: “Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study,” presented by Dr. Nina Khanna of th...

The FDA approves Cerus' (CERS) Intercept Blood System for cryoprecipitation, specifically for producing pathogen-reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.Fibrinogen is a protein t...

Cerus Corporation (Nasdaq: CERS) today announced that the US Food and Drug Administration (FDA) has granted approval of the INTERCEPT Blood System for Cryoprecipitation. The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of b...

In spite of common misconception, Cerus is not among the few companies to profit in treatment or prevention of the COVID-19 virus. The implementation of the INTERCEPT Blood System in the United States would serve to further deplete the critically low present blood supply. Scores o...

Image source: The Motley Fool. Cerus Corporation (NASDAQ: CERS) Q3 2020 Earnings Call Oct 29, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Cerus Corporation (CERS) Q3 2020 Earnings Call Transcript

The following slide deck was published by Cerus Corporation in conjunction with their 2020 Q3 earnings call. For further details see: Cerus Corporation 2020 Q3 - Results - Earnings Call Presentation

Cerus Corporation (CERS) Q3 2020 Earnings Conference Call October 29, 2020 4:30 PM ET Company Participants Tim Lee - Investor Relations Obi Greenman - President and Chief Executive Officer Kevin Green - Chief Financial Officer Vivek Jayaraman - Chief Operating Officer Carol Moore - SVP of Reg...

Cerus (CERS): Q3 GAAP EPS of -$0.08 beats by $0.02.Revenue of $23.61M (+31.0% Y/Y) misses by $1.07M.Press Release For further details see: Cerus EPS beats by $0.02, misses on revenue

Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2020. Recent developments and highlights include: Q3 2020 Total Revenue of $29.2 million - driven by significant year-over-year platelet kit sales growth in the...